Granulocyte transfusion therapy

Journal of Intensive Care Medicine

Volumn 30, Issue 2, 2015, Pages 79-88

  Marfin, Anthony A ^a,b   Price, Thomas H ^a,c  

^a PUGET SOUND BLOOD CENTER   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

apheresis; bacterial infection; chemotherapy; fungal infection; G CSF; granulocyte transfusion; granulocytopenia; neutropenia; neutrophil transfusion; stem cell transplantation

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CORTICOSTEROID; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR;

BACTERIAL INFECTION; BLOOD DONOR; CLINICAL EFFECTIVENESS; DONOR SELECTION; GRAFT RECIPIENT; GRANULOCYTE; GRANULOCYTE TRANSFUSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MYCOSIS; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SAFETY; TREATMENT INDICATION; ADVERSE EFFECTS; BACTERIAL INFECTIONS; BONE MARROW TRANSPLANTATION; DONOR; DOSE RESPONSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; MYCOSES; PRACTICE GUIDELINE; PROCEDURES; TRANSPLANTATION; TREATMENT OUTCOME;

BACTERIAL INFECTIONS; BONE MARROW TRANSPLANTATION; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYCOSES; NEUTROPENIA; PRACTICE GUIDELINES AS TOPIC; TISSUE DONORS; TREATMENT OUTCOME;

EID: 84920982415     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066613498045     Document Type: Review

References (81)

1. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011 ; 52 ((4)). e56 - e93
2. Aapro MS, Bohlius J, Cameron DA, et al. European organisation for research and treatment of cancer. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011 ; 47 ((1)). 8-32
3. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010 ; 363 ((22)). 2091-2101
4. Cullen M, Baijal S. Prevention of febrile neutropenia: use of prophylactic antibiotics. Br J Cancer. 2009 ; 101 ((suppl 1)). S11 - S14
5. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006 ; 106 ((10)). 2258-2266
6. Morse EE, Freireich EJ, Carbone PP, Bronson W, Frei E. The transfusion of leukocytes from donors with chronic myelocytic leukemia to patients with leukopenia. Transfusion. 1966 ; 6 ((3)). 183-192
7. Bashir S, Stanworth S, Massey E, Goddard F, Cardigan R. Neutrophil function is preserved in a pooled granulocyte component prepared from whole blood donations. Br J Haematol. 2008 ; 140 (6). 701-711
8. Graw RG, Herzig G, Perry S, Henderson ES. Normal granulocyte transfusion therapy: treatment of septicemia due to gram-negative bacteria. N Engl J Med. 1972 ; 287 ((8)). 367-371
9. Stanworth S, Massey E, Hyde C, et al. Granulocyte transfusions for treating infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev. 2005 ; (3). CD005339
10. Massey E, Paulus U, Doree C, Stanworth S. Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev. 2009 ; (1). CD005341
11. Petty JM, Lenox CC, Weiss DJ, Poynter ME, Suratt BT. Crosstalk between CXCR4/SDF-1 and VLA-4/VCAM-1 pathways regulates neutrophil retention in the bone marrow. J Immunol. 2009 ; 182 ((1)). 604-612
12. Rettig MP, Ansstas G, DiPersio JF. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia. 2012 ; 26 ((1)). 34-53
13. Dutcher JP Modern Transfusion Therapy. Dutcher JP, ed. Boca Raton, FL: CRC Press Inc ; 1990: 135-156.
14. Hubel K, Dale DC, Engert A, Liles WC. Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases. J Infect Dis. 2001 ; 183 ((2)). 321-328
15. Djerassi I. Transfusions of filtered granulocytes. N Engl J Med. 1975 ; 292 ((15)). 803-804
16. Hammerschmidt DE, Craddock PR, McCullough F, Kronenberg RS, Dalmasso AP, Jacob HS. Complement activation and pulmonary leukostasis during nylon fiber filtration leukapheresis. Blood. 1978 ; 51 ((4)). 721-730
17. Strauss RG, Klein HG, Leitman SF, et al. Preparation of granulocyte concentrates by apheresis: collection modalities in the USA. Vox Sang. 2011 ; 100 ((4)). 426-433
18. Liles WC, Rodger E, Dale DC. Combined administration of G-CSF and dexamethasone for the mobilization of granulocytes in normal donors: optimization of dosing. Transfusion. 2000 ; 40 ((6)). 642-644
19. Liles WC, Huang JE, Llewellyn C, SenGupta D, Price TH, Dale DC. A comparative trial of granulocyte-colony-stimulating factor and dexamethasone, separately and in combination, for the mobilization of neutrophils in the peripheral blood of normal volunteers. Transfusion. 1997 ; 37 ((2)). 182-187
20. Stroncek DF, Yau YY, Oblitas J, Leitman SF. Administration of G-CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone. Transfusion. 2001 ; 41 ((8)). 1037-1044
21. Ikemoto J, Yoshihara S, Fujioka T, et al. Impact of the mobilization regimen and the harvesting technique on the granulocyte yield in healthy donors for granulocyte transfusion therapy. Transfusion. 2012 ; 52 (12). 2646-2652
22. Caspar CB, Seger RA, Burger J, Gmür J. Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor. Blood. 1993 ; 81 ((11)). 2866-2871
23. Bensinger WI, Price TH, Dale DC, et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood. 1993 ; 81 ((7)). 1883-1888
24. Adkins D, Spitzer G, Johnston M, Velasquez W, Dunphy F, Petruska P. Transfusions of granulocyte-colony-stimulating factor-mobilized granulocyte components to allogeneic transplant recipients: analysis of kinetics and factors determining posttransfusion neutrophil and platelet counts. Transfusion. 1997 ; 37 ((7)). 737-748
25. Chatta GS, Price TH, Allen RC, Dale DC. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood. 1994 ; 84 ((9)). 2923-2929
26. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002 ; 34 ((7)). 909-917
27. Price TH, Chatta GS, Dale DC. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood. 1996 ; 88 ((1)). 335-340
28. Liles WC, Huang JE, van Burik JH, Bowden RA, Dale DC. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. J Infect Dis. 1997 ; 175 ((4)). 1012-1015
29. Eyles JL, Roberts AW, Metcalf D, Wicks IP. Granulocyte colony-stimulating factor and neutrophils-forgotten mediators of inflammatory disease. Nat Clin Pract Rheumatol. 2006 ; 2 ((9)). 500-510
30. Drewniak A, van Raam BJ, Geissler J, et al. Changes in gene expression of granulocytes during in vivo granulocyte colony-stimulating factor/dexamethasone mobilization for transfusion purposes. Blood. 2009 ; 113 ((23)). 5979-5998
31. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun. 1993 ; 61 ((11)). 4870-4877
32. Filep JG, Delalandre A, Payette Y, Foldes-Filep E. Glucocorticoid receptor regulates expression of l-selectin and CD11/CD18 on human neutrophils. Circulation. 1997 ; 96 ((1)). 295-301
33. Quillen K, Yau YY, Leitman SF. The determinants of granulocyte yield in 1198 granulocyte concentrates collected from unrelated volunteer donors mobilized with dexamethasone and granulocyte colony-stimulating factor: a 13-year experience. Transfusion. 2009 ; 49 ((3)). 421-426
34. Hubel K, Carter RA, Liles WC, et al. Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion. 2002 ; 42 ((11)). 1414
35. Price TH, Bowden RA, Boeckh M, et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood. 2000 ; 95 ((11)). 3302-3309
36. Stroncek DF, Clay ME, Petzoldt ML, et al. Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion. 1996 ; 36 ((7)). 601-610
37. Anderlini P, Przepiorka D, Seong D, et al. Clinical toxicity and laboratory effects of granulocyte-colony stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion. 1996 ; 36 ((7)). 590-595
38. Quillen K, Byrne P, Yau YY, Leitman SF. Ten-year follow-up of unrelated volunteer granulocyte donors who have received multiple cycles of granulocyte-colony-stimulating factor and dexamethasone. Transfusion. 2009 ; 49 ((3)). 513-518
39. Pulsipher MA, Chitphakdithai P, Miller JP, et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the national marrow donor program. Blood. 2009 ; 113 (15). 3604-3611
40. Strauss RG, Lipton KS. Glucocorticoid stimulation of neutrophil donors: a medical, scientific and ethical dilemma. Transfusion. 2005 ; 45 ((11)). 1697-1699
41. Heim KF, Fleisher TA, Stroncek DF, et al. The relationship between alloimmunization and posttransfusion granulocyte survival: experience in a chronic granulomatous disease cohort. Transfusion. 2011 ; 51 ((6)). 1154-1162
42. Dancey JT, Deubelbeiss KA, Harker LA, Finch CA. Neutrophil kinetics in man. J Clin Invest. 1976 ; 58 ((3)). 705-715
43. Kim KH, Lim HJ, Kim JS, et al. Therapeutic granulocyte transfusions for the treatment of febrile neutropenia in patients with hematologic diseases: a 10-year experience at a single institute. Cytotherapy. 2011 ; 13 ((4)). 490-498
44. Ang AL, Linn YC. Treatment of severe neutropenic sepsis with granulocyte transfusion in the current era - experience from an adult haematology unit in Singapore. Transfus Med. 2011 ; 21 ((1)). 13-24
45. Adkins DR, Goodnough LT, Shenoy S, et al. Effect of leukocyte compatibility on neutrophil increment after transfusion of granulocyte colony-stimulating factor-mobilized prophylactic granulocyte transfusions and on clinical outcomes after stem cell transplantation. Blood. 2000 ; 95 ((11)). 3605-3612
46. Hester JP, Dignani MC, Anaissie EJ, Kantarjian HM, O'Brien S, Freireich EJ. Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection. J Clin Apheresis. 1995 ; 10 ((4)). 188-193
47. Seidel MG, Minkov M, Witt V, et al. Granulocyte transfusions in children and young adults: does the dose matter?. J Pediatr Hematol Oncol. 2009 ; 31 ((3)). 166-172
48. Higby DJ, Yates JW, Henderson ES, Holland JF, et al. Filtration leukapheresis for granulocyte transfusion therapy. clinical and laboratory studies. N Engl J Med. 1975 ; 292 ((15)). 761-766
49. Herzig RH, Herzig GP, Graw RG, Bull MI, Ray KK. Successful granulocyte transfusion therapy for gram-negative septicemia - a prospectively randomized controlled study. N Engl J Med. 1977 ; 296 ((13)). 701-705
50. Alavi JB, Root RK, Djerassi I, et al. A randomized clinical trial of granulocyte transfusions for infection in acute leukemia. N Engl J Med. 1977 ; 296 ((13)). 706-711
51. Clift RA, Sanders JE, Thomas ED, Williams B, Buckner CD. Granulocyte transfusions for the prevention of infection in patients receiving bone-marrow transplants. N Engl J Med. 1978 ; 298 ((19)). 1052-1057
52. Vamvakas EC, Pineda AA. Meta-analysis of clinical studies of the efficacy of granulocyte transfusions in the treatment of bacterial sepsis. J Clin Apher. 1996 ; 11: 1-9
53. Pammi M, Brocklehurst P. Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropenia. Cochrane Database Syst Rev. 2011 ; ( 10 ):
54. Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis. 2006 ; 43 ((suppl 1)). S3 - S14
55. Price TH. Granulocyte transfusion: current status. Semin Hematol. 2007 ; 44 ((1)). 15-23
56. Seidel MG, Peters C, Wacker A, et al. Randomized phase III study of granulocyte transfusions in neutropenic patients. Bone Marrow Transplant. 2008 ; 42 ((10)). 679-684
57. Safdar A, Hanna HA, Boktour M, et al. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer. 2004 ; 101 ((12)). 2859-2865
58. Ofran Y, Avivi I, Oliven A, et al. Granulocyte transfusions for neutropenic patients with life-threatening infections: a single centre experience in 47 patients, who received 348 granulocyte transfusions. Vox Sang. 2007 ; 93 ((4)). 363-369
59. Quillen K, Wong E, Scheinberg P, et al. Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. Haematologica. 2009 ; 94 ((12)). 1661-1668
60. Al-Tanbal H, Al Humaidan H, Al-Nounou R, Roberts G, Tesfamichael K, Owaidah T. The value and practicality of granulocyte transfusion: a single oncology centre experience. Transfus Med. 2010 ; 20 ((3)). 160-168
61. Pham HP, Rogoza K, Stotler B, et al. Granulocyte transfusion therapy in pediatric patients after hematopoietic stem cell transplantation: a 5-year single tertiary care center experience. J Pediatr Hematol Oncol. 2012 ; 34 ((8)). e332 - e336
62. Kerr JP, Liakopolou E, Brown J, et al. The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogeneic stem cell transplantation. Br J Haematol. 2003 ; 123 ((1)). 114-118
63. Stroncek DF, Leonard K, Eiber G, Malech HL, Gallin JI, Leitman SF. Alloimmunization after granulocyte transfusions. Transfusion. 1996 ; 36 ((11-12)). 1009-1015
64. Wright DG, Robichaud KJ, Pizzo PA, Deisseroth AB. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med. 1981 ; 304 ((20)). 1185-1189
65. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the infectious disease society of America, and the American society of blood and marrow transplantation. Morb Mortal Wkly Rep. 2000 ; 49 ((rr10)). 12
66. Vij R, DiPersio JF, Venkatraman P, et al. Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation. Blood. 2003 ; 101 ((5)). 2067-2069
67. Nichols WG, Price T, Boeckh M. Donor serostatus and CMV infection and disease among recipients of prophylactic granulocyte transfusions. Blood. 2003 ; 101 ((12)). 5091-5092
68. ElebuteMMasseyEBenjaminSStanworthSNavarreteCLucasG. Clinical guidelines for the use of granulocyte transfusions. information document INF276/2 (effective: 31/01/11). http://hospital.blood.co.uk/library/pdf/INF276-2.pdf. Accessed August, 2012.
69. NIH clinical trials. http://clinicaltrials.gov/ct2/show/NCT00627393. Accessed August, 2012.
70. Hubel K, Rodger E, Gaviria JM, Price TH, Dale DC, Liles WC. Effective storage of granulocytes collected by centrifugation leukapheresis from donors stimulated with granulocyte-colony-stimulating factor. Transfusion. 2005 ; 45 ((12)). 1876-1889
71. Massey E, Harding K, Kahan BC, et al. The granulocytes in neutropenia 1 [GIN 1] study: a safety study of granulocytes collected from whole blood and stored in additive solution and plasma. Transfus Med. 2012 ; 22 ((4)). 277-284
72. Eash KJ, Means JM, White DW, Link DC. CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions. Blood. 2009 ; 113 ((19)). 4711-4719
73. Bonig H, Watts KL, Chang KH, Kiem HP, Papayannopoulou T. Concurrent blockade of alpha4-integrin and CXCR4 in hematopoietic stem/progenitor cell mobilization. Stem Cells. 2009 ; 27 ((4)). 836-837
74. Bensinger WI. Allogeneic transplantation: peripheral blood vs. bone marrow. Curr Opin Oncol. 2012 ; 24 ((2)). 191-196
75. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2003 ; 102 ((8)). 2728-2730
76. McDermott DH, Liu Q, Ulrick J, et al. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood. 2011 ; 118 ((18)). 4957-4962
77. Dale DC, Bolyard AA, Kelley ML, et al. The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome. Blood. 2011 ; 118 ((18)). 4963-4966
78. Hino M, Suzuki K, Yamane T, et al. Ex vivo expansion of mature human neutrophils with normal functions from purified peripheral blood CD34+ haematopoietic progenitor cells. Br J Haematol. 2000 ; 109 ((2)). 314-321
79. McNiece I, Briddell R. Ex vivo expansion of hematopoietic progenitor cells and mature cells. Exp Hematol. 2001 ; 29 ((1)). 3-11
80. Marturana F, Timmins NE, Nielsen LK. Short-term exposure of umbilical cord blood CD34+ cells to granulocyte-macrophage colony-stimulating factor early in culture improves ex vivo expansion of neutrophils. Cytotherapy. 2011 ; 13 ((3)). 366-377
81. Dick EP, Prince LR, Sabroe I. Ex vivo-expanded bone marrow CD34+ derived neutrophils have limited bactericidal ability. Stem Cells. 2008 ; 26 ((10)). 2552-2563